Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced that its wholly-owned subsidiary MNTX Royalties Sub LLC has entered into a $50 million ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE